HEALTHMay 28 · 08:30 UTCSTAT NEWSJohn Wilkerson

STAT+: Trump’s drug-pricing deals set to be tested by new product launches

President Trump's most-favored-nation drug pricing deals with 17 drugmakers will be tested by three new prescription drugs set to launch soon. The drugs, Baxfendy (hypertension), Awiqli (insulin), and Veppanu (cancer), will offer the first public insight into the practical impacts of these secretive pricing agreements.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

BaxfendytopicAwiqlitopicVeppanutopicAstraZenecaorganizationNovo NordiskorganizationArvinasorganizationPfizerorganizationRigel PharmaceuticalsorganizationTrumppersonmost-favored-nation dealstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHApr 23 · 16:59 UTC
Trump cuts drug price deal with Regeneron
BUSINESSMay 12 · 07:48 UTC
STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
HEALTHApr 23 · 20:53 UTC
Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
POLITICSApr 23 · 20:10 UTC
Trump unveils Regeneron deal to lower drug prices
HEALTHApr 24 · 16:32 UTC
Full list of prescription drugs - including cholesterol-busting medication taken by millions - that could see massive price cuts under Trump's new deal
HEALTHMay 6 · 17:03 UTC
STAT+: Administration report on most favored nation drug pricing raises new details — and questions